HALO
Halozyme Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$110.29
−0.42%Forward multiples
Based on analyst estimates
- P/E forward
- 11.54x
- P/E 2026E
- 13.16x
- P/E 2027E
- 10.66x
- P/E 2028E
- 9.38x
- P/S forward
- 6.20x
Trailing multiples
Trailing twelve months
- P/E TTM
- 31.33x
- PEG TTM
- 0.18x
- Price / book
- 87.21x
- Price / sales
- 7.52x
- Price / cash flow
- 15.29x
Enterprise value
- Enterprise value
- $14.4B
- EV / sales
- 8.68x
- EV / EBITDA
- 20.21x
- EV / EBIT
- 15.28x
- Market cap
- $12.5B
Trailing, forward and enterprise-value multiples for the requested listing · Data as of Jun 1, 2026